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Abstract
Metformin, a well-known insulin-sensitizer commonly used for type 2 diabetes therapy, has recently emerged as potentially
very attractive drug also in oncology. It is cheap, it is relatively safe and many reports have indicated effects in cancer
prevention and therapy. These desirable features are particularly interesting for pediatric sarcomas, a group of rare tumors
that have been shown to be dependent on IGF and insulin system for pathogenesis and progression. Metformin exerts anti-
mitogenic activity in several cancer histotypes through several molecular mechanisms. In this paper, we analyzed its effects
against osteosarcoma, Ewing sarcoma and rhabdomyosarcoma, the three most common pediatric sarcomas. Despite in vitro
metformin gave remarkable antiproliferative and chemosensitizing effects both in sensitive and chemoresistant cells, its
efficacy was not confirmed against Ewing sarcoma xenografts neither as single agent nor in combination with vincristine.
This discrepancy between in vitro and in vivo effects may be due to hypoxia, a common feature of solid tumors. We provide
evidences that in hypoxia conditions metformin was not able to activate AMPK and inhibit mTOR signaling, which likely
prevents the inhibitory effects of metformin on tumor growth. Thus, although metformin may be considered a useful
complement of conventional chemotherapy in normoxia, its therapeutic value in highly hypoxic tumors may be more
limited. The impact of hypoxia should be considered when novel therapies are planned for pediatric sarcomas.
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Introduction
The IGF system has an important role in tumorigenesis and
cancer progression [1]. In addition, metabolic factors such as
obesity and hyperinsulinaemia have been associated with in-
creased overall cancer risk [2]. Although many factors have been
postulated to mediate effects of obesity on cancer, recent research
has focused on insulin as a potentially relevant mediator [3]. The
recognition that the expression of insulin receptors (IR) is not
confined to classic insulin-target tissues such as the liver, muscle
and fat, but that it extends to normal and transformed tissues raises
several ques-tions. The IR is expressed at two isoforms that differ
at the carboxyl terminus of the A subunits by 12 amino acids [4].
The IR-B is the classic IR that regulates glucose uptake and binds
insulin with high affinity but binds IGFs poorly. Conversely, the
IR-A binds both insulin and IGF-2 with high affinity but IGF-1
with low affinity. In some conditions like fetal growth, cancer and
diabetes, IR may display some non-metabolic effects like cell
proliferation and migration and may affect metastasis and tumor
progression. Over-expression of IR-A is in fact emerging as a
feature of cancer cells where it mediates cell survival, proliferation,
and migration under insulin and IGF-2 stimulus [1,4,5]. An
autocrine loop involving IGF-2 and IR-A is active in different
sarcomas, such as rhabdomyosarcoma and osteosarcoma cells
[6,7,8]. Recently, we have demonstrated exclusive presence of IR-
A in Ewing sarcoma [9]. Moreover, the ratio of IGF-1R:IR-A in
favor of IR-A seems to be responsible of native and acquired
resistance of some Ewing sarcoma to both monoclonal antibodies
and small tyrosine kinase inhibitors (TKI) anti-IGF-1R and it may
also explain the lower levels of sensitivity of other sarcomas, such
as rhabdomyosarcoma and osteosarcoma to these targeted
therapies. In cells resistant to anti-IGF-1R drugs, we observed
increased expression of IGF-2 together with increased levels of IR-
A; consequently, we presumed these cells undergo a switch from
IGF-1/IGF-1R to IGF-2/IR-A dependency to maintain prolifer-
ation, migration and metastasis. The proliferative role of IR-A in
resistant cells was supported also by increased sensitivity to
proliferative effects of insulin while silencing of IR induced
inhibition of cell growth [9].
In this perspective, the anti-diabetic drug metformin, a
biguanide derivative widely used as first-line pharmacotherapy in
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non-insulin-dependent diabetes mellitus (T2DM), has recently
gained attention in cancer research [10,11,12,13]. The primary
systemic effect of metformin is to lower glucose levels through
reduced hepatic gluconeogenesis and increase glucose uptake in
peripheral tissues such as muscle and fat. Thus indirect benefits of
metformin is a decrease in insulin, a growth promoting hormone,
suggesting that metformin could affect tumor growth and reduce
the risk of cancer. Indeed, epidemiological investigations report
that metformin treatment is associated with a decreased incidence
of cancers in several organs, such as breast, prostate, colon, and
pancreatic cancer [14,15,16,17]. In addition, in clinical settings,
metformin improves outcome of diabetic cancers patients, either
as single agent as well as in combination with chemotherapeutic
drugs, suggesting a potential role on cancer therapy [18,19].
Metformin was also reported to exert direct effects against cancer
cells. At the cellular level, there is considerable evidence showing
that metformin partially inhibits complex-I of the respiratory chain
in mitochondria, leading to reduced oxida-tive phosphorylation
and reduced ATP production. This leads to cellular ATP deficit
and activation of AMP kinase (AMPK) which is a cellular energy
sensor that downregulates cellular processes that consume energy
[20]. In fact, once activated, AMPK restores cellular energy levels
by stimulating the catabolic pathway, such as glucose uptake,
glycolysis and fatty acid oxidation and stop ATP-consuming
processes such as fatty acid, cholesterol and protein synthesis.
Furthermore, AMPK activation leads to regulation of multiple
downstream pathways involved in the control of cellular prolifer-
ation, including inhibition of the mTOR downstream pathway
[21]. Although there are still gaps in the understanding of
metformin mechanisms of action, mounting evidences indicate an
effective role of metformin in cancer therapy.
In the present study we evaluated the in vitro and in vivo
therapeutic effects of metformin against osteosarcoma, rhabdo-
myosarcoma and Ewing sarcoma, the three most common
pediatric sarcomas. In addition, drug-drug interactions between
conventional chemotherapeutic agents and metformin were
investigated together with the analysis of its anti-proliferative
effects in hypoxia conditions.
Materials and Methods
Ethics Statement
All animal experiments were authorized by the Experimental
protocols approved by the Institutional Animal Care and Use
Committee of the University of Bologna, and forwarded to the
Italian Ministry of Health (letter 4783-X/10). Mice were treated
according to institutional and European Union guidelines.
Drugs
Metformin, doxorubicin and vincristine was purchased from
Sigma, (St. Louis, MO, USA). Actinomycin-D was purchased by
Ovation Healthcare International (Dublin, Ireland). The PI3K/
mTOR dual inhibitor NVP-BEZ235 was kindly provided by
Novartis (Basel, Switzerland)... D-18851, an ifosfamide analog not
requiring metabolic activation, was kindly provided by Baxter
Oncology GmbH (Frankfurt, Germany). ). Insulin was purchased
from Novo Nordisk (Bagsvaerd, Denmark) and IGF-1 from
Millipore (Billerica, MA, USA). Working dilutions of all drugs
were prepared immediately before use.
Cell lines
A panel of four osteosarcoma, seven Ewing sarcoma, and three
rhabdomyosarcoma human cell lines were analyzed. Saos-2, U-
2OS, MG-63, SK-ES-1, SK-N-MC, and RD-ES were provided by
American Type Culture Collection, ATCC; the alveolar rhabdo-
myosarcoma cell line SJ-RH30 was kindly provided by Dr. A.
Rosolen (University of Padua, Padua, Italy)[22]; Ewing sarcoma
cell lines TC-71 and 6647 were kindly provided by T.J. Triche
(Children’s Hospital, Los Angeles, CA); the ASP14 cell line, a
stable cell line generated from A673 ES cell line transfected with
doxycycline(DOX)-inducible shRNA targeting EWS-FLI1 was
kindly provided by H. Kovar (St. Anna Kinderkrebsforshung,
Vienna). The osteosarcoma IOR/OS10 and the Ewing cell line
LAP-35 were obtained in the Experimental Oncology Lab, Rizzoli
Institute (Bologna) and were previously described [8,23]. The RD/
18, a clone of the commercially available cell line RD (Flow
Laboratories), and the CC-A cell lines were kindly gifted by Prof.
P.L. Lollini, University of Bologna and previously characterized
[24,25]. The Ewing sarcoma TC/DOXO8 and the osteosarcoma
U-2/DOXO35 were generated by transfection with an expression
vector containing full-length MDR1 cDNA and selected in
doxorubicin [26,27]. Cells resistant to anti-IGF-1R agents were
obtained from TC-71 Ewing sarcoma cell line, as recently
described and characterized [5,9], and referred as TC/AVE
(resistant to AVE1642 MAb, Immunogen Waltham, AM TC/CP
(resistant to CP-751,871/Figitumumab, Pfizer, San Diego, CA ),
or TC/AEW (resistant to NVP-AEW541, Novartis) All the cell
lines have been recently authenticated by STR analysis using
genRESVR MPX-2 and genRESVR MPX-3 kits (serac, Bad
Homburg, Germany). The following loci were verified: D16S539,
D18S51, D19S433, D21S11, D2S1338, D3S1358, D5S818,
D8S1179, FGA, SE33, TH01, TPOX VWA. Last control was
performed in November 2012. All these cell variants were tested
for mycoplasma contamination every 3 months (last control,
March 2013) by MycoAlert mycoplasma detection set (Lonza,
Nottingham, Ltd). Cultures were grown in a humidified incubator
at 37uC with 5% CO2 and maintained in standard medium
(Iscove Modified Dulbecco’s medium, IMDM, plus 10% fetal
bovine serum, FBS). For hypoxic condition, TC-71 and ASP-14
Ewing sarcoma cells were grown in IMDM containing the
hypoxia-mimetic agents cobalt chloride (CoCl2) (200 uM) (Sig-
ma,St Louis, MO, USA).
Cell culture experiments
To assess cell growth, MTT assay (Roche, Indianapolis, IN) was
used according to manufacturer’s instructions. Cells were plated
into 96 well-plates (range 2,500–10,000 cells/well) in standard
medium. After 24 hours, various concentrations of metformin (1–
50 mM) were added and cells exposed up to 72 hours. In
combination experiments, cells were treated for 72h with
metformin alone (control) or combined in fixed ratio with DXR,
VCR, ACT-D and IFO, respectively. For analysis of cell cycle,
after 24 to 72 hours of treatment, cell cultures were incubated with
10 mmol/L bromodeoxyuridine (Sigma) for 1 hour in CO2
atmosphere at 37uC and processed accordingly to procedures
previously described. For analysis of DNA content and evaluation
of apoptosis, cells were fixed with cold 70% ethanol, treated with
0.5 mg/mL RNase, and stained with 20 mg/mL propidium
iodide. [28,29]. Anchorage-independent growth was determined
after seeding of 3,300 cells/dish in 0.33% agarose (SeaPlaque,
FMC BioProducts, Rockland, ME) with a 0.5% agarose underlay
[28].
In combined experiments with IGFs ligands, cells were serum
starved for 18h and treated with IGF-I (50 ng/ml) or insulin
(10 nM) alone or in combination with metformin (10 mM) for
48h. For protein analysis, starved cells were pre-treated with
metformin (10 mM) for 4h and then exposed to IGF-I (50 ng/ml)
or insulin (10nM) for 15min.
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Western blotting
Cells were treated with metformin (10 mM) for 30min to 24h or
left untreated and cell lysates were prepared and processed as
previously described [28]. The following antibodies (Ab) were
used: anti-phospho-AMPKa (thr172) Ab, anti-AMPK Ab, anti-
phospho S6 (Ser240/244) Ab, anti-S6 mAb, anti-ERK pAb, (Cell
Signaling Technology, Beverly, MA); anti-phospho-ERK
(Tyr202/Tyr204) Ab (Covance, Princeton, NJ); anti-HIF1a Ab,
and anti-Beta-actin mAb (Santa Cruz Biotechnology, San Diego,
CA, USA). Anti-rabbit or anti-mouse antibodies conjugated to
horseradish peroxidase (GE Healthcare, Piscataway, NJ) were used
as secondary antibody.
Real Time PCR
Total IR and IGF-1R was also measured by using the absolute
quantification assay, as previously described [9].
L-Lactate and ATP measurement
Briefly, TC-71, SK-N-MC and 6647 cells were seeded in 6 well
or 96 well plates depending on the assay. 24 hours later medium
was removed and cells were incubated with either vehicle or
metformin (10 mM) for 24–48 h. Following cell treatments, the
medium was removed from cells and lactate levels in the
extracellular medium were measured using the Lactate Colori-
metric Assay Kit (Abcam, Cambridge, MA, USA), accordingly to
manufacturer’s instruction. This kit detects lactate levels in
samples from concentrations of 0.02–10 mM. Lactate concentra-
tion was normalized to sample cell number. Cellular ATP levels
were measured using the CellTiter-Glo Luminescent Assay
(Promega), accordingly to manufacturer’s instruction.
Ki-67 staining
Adherent cells grown on coverslips for 48 hours were fixed in
cold methanol, blocked with 4% BSA/PBS for 1 hour at room
temperature, and incubated with anti-Ki-67 pAb (Santa Cruz
Biotechnology, San Diego, CA, USA) (1:50). Polyclonal anti-rabbit
FITC (Dako, Glostrup, Denmark) (1:80) was used as secondary
antibody. Nuclei were counterstained with Hoechst 33256
(Sigma). Images were taken using Nikon ECLIPSE 90i image
analysis system (Nikon, Italy). In each sample, the percentage of
Ki-67-positive cells was quantified on at least 500 cells and
expressed as Ki-67 labeling index (LI). Images acquisition and
processing were conducted using the NIS-Elements A.R. 3,10
software. Acquisition parameters were as follow: NA objective
0.75; R.I. 1, image size: 256061920; exp ME:3 sec; noise
reduction ON.
Receptor measurement by enzyme-linked
immunosorbent assay
The characteristics and specificity of IR or IGF-1R enzyme-
linked immunoabsorbent assays have been previously described
[30].
In vivo treatment with Metformin alone or in
combination with vincristine
Athymic Crl:CD1-Foxn1 nu (nude) mice, 4–5 weeks old, were
purchased from Charles River Italy. For the evaluation of
treatment effectiveness, 7 days after TC-71 cells subcutaneous
injection, when tumors started to be measurable, mice were
randomized into control and treated groups. Mice treated with
metformin received the drug either in drinking water (200 mg/Kg,
for 3 weeks) or through daily intratumor injection (200 mg/Kg in
PBS, 5 days weekly, for 3 weeks) or through daily gavage at
500 mg/kg, 5 days weekly, for 2 weeks. Vincristine was given i.p.
(1 mg/Kg/d) on days 7 and 8 after cell injection. For combination
therapies, mice received metformin (500 mg/Kg p.o.) and
vincristine (1 mg/Kg i.p. on day 7 and 8 after cell injection).
The control groups were treated with PBS intratumor or water
only p.o. Tumor volume was calculated as p[!(a?b)]3/6 where a is
the maximal tumor diameter and b is the tumor diameter
perpendicular to a.
Immunohistochemistry
Immunohistochemical staining was done on 3-mm paraffin
sections of xenografts derived from in vivo experiments. Briefly,
dewaxing and antigen retrieval have been obtained using W-CAP
TEC BUFFER pH 6 (Bio-Optica, Thermo Fischer Scientific Inc.
Fremont, CA) at 98uC for 20–25minutes. Inhibition of endoge-
nous peroxidases was performed in 3% H2O2 solution and the
slides were subsequently rinsed in phosphate buffered saline
solution (PBS) 1X with 0.01% of detergent Tween-20 (PBS 1X-
Tween). All the following incubation steps were performed in
humid chamber at room temperature. Sections were incubated for
5 minutes with Ultra V Block solution (Ultravision LP, LabVision
Corporation, Thermo Fisher Scientific Inc, Fremont, CA) and
then washed in PBS 1X-Tween. They were subsequently
incubated for 1 hour with HIF1-alfa (1:700, Novus Biologicals,
Littleton, CO), anti-phospho-AMPKa (thr172) (1:20, Cell Signal-
ing Technology) primary antibody and rinsed in PBS 1X-Tween.
Sections were further incubated with Primary Antibody Enhancer
solution (Ultravision LP, LabVision Corporation) for 20 minutes.
After several washes in PBS 1XTween, sections were incubated for
30 minutes with horseradish peroxide–polymer solution (Ultravi-
sion LP, LabVision Corporation). Reaction was revealed with
Diaminobenzidine (DAB) solution for 3 minutes and counter-
stained with hematoxylin.
Statistical analysis
Correlations between two variables were obtained by Spear-
man’s test. IC50 values were calculated from linear transformation
of dose-response curves. To define drug-drug interactions (in terms
of synergism, additivity, or antagonism), the combination index
(CI) of each two-drug treatment was calculated with the
isobologram equation [31] by using the CalcuSyn software
(Biososoft, Ferguson, MO).
Results
The effects of metformin on sarcoma cells growth were
investigated in a panel of seven Ewing sarcoma, four osteosarco-
ma, and three rhabdomyosarcoma human cell lines. Ewing
sarcoma appeared as the most sensitive histotype when cells were
grown in monolayer conditions (Figure 1A). However, also among
Ewing sarcoma cell lines metformin was variably effective: TC-71
cells were the most sensitive (IC50 value of 8.1 mM), while RD-ES
and 6647 were the most resistant (IC50 value of 39.9 mM and
19.9 mM, respectively). To verify whether metformin is able to
affect tumorigenic properties of Ewing sarcoma cells too, we
analyzed their anchorage-independent growth by a soft-agar assay
using 10–50 nM of metformin. Both doses of metformin gave
significant reduction in the number and size of the Ewing sarcoma
TC-71 and osteosarcoma U-2 OS colonies, while more limited
effects were observed in the rhabdomyosarcoma RD/18 cell line
(Figure 1B). The variable efficacy of metformin did not appear to
be related to differences in IGFs and insulin pathways. Indeed, no
correlation was found between IGF-1R/IR-A expression levels
and sensitivity to metformin (Table 1). In addition, in cells resistant
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to anti-IGF-1R therapies, where we found an increased expression
of IR-A [5] together with down-regulation of IGF-1R, the anti-
proliferative effects were similar to sensitive cells (Figure 2A).
Moreover, when Ewing sarcoma cells were exposed to exogenous
IGF1 and/or insulin, metformin prevented IGF-1 and Insulin-
induced proliferation and maintained its anti-proliferative effects.
TC-71 and 6647 were chosen as representative of a cell line with
IGF1/IGF1R or Insulin/IR dependency (Figure 2B). The anti-
proliferative effect of metformin was obtained independently from
MAPK/ERK pathway, which was induced by ligand exposure
and was not affected by metformin (Figure 2C), but rather related
to AMPK inhibition (Figure 3). Several reports demonstrate
AMPK as a major target of metformin [10,11,12,13]. AMPK may
be activated through direct (via increase of AMP/ATP ratio) or
indirect (via LKB1-mediated phosphorylation) mechanisms. In our
panel of cell lines expression of LKB1 was verified in six Ewing
sarcoma, four osteosarcoma, and 3 rhabdomyosarcoma cell lines
(Figure 3A) and did not appear to modulate sensitivity to
metformin (Table 1). After 24h of metformin treatment, statisti-
cally significant dose-dependent decrease in overall intracellular
ATP contents was observed in TC-71 and SK-N-MC EWS cell
lines, while treatment of 6647 cells, one of the most resistant Ewing
sarcoma cells, induced only a modest reduction of the ATP
concentration (Figure 3B). When mitochondrial respiration is
impaired, cells compensate and increase aerobic glycolysis to
improve their bioenergetics. Accordingly, metformin treatment
significantly increased L-lactate production in TC-71 and SK-N-
MC cell lines confirming the induced glycolytic shift (Figure 3B).
These results demonstrate that, in Ewing sarcoma cells, metformin
initiates a strong metabolic stress which very likely leads to direct
activation of AMPK. Differences in time-dependent activation of
AMPK reflect the variable effectiveness of metformin: in TC-71,
the most sensitive cell line, metformin induced phosphorylation of
AMPKa after 30min of treatment, in SK-N-MC after 1h, while in
6647 we observed increased levels of p-AMPKa after 6 h (Figure
3C). The activated form of AMPK inhibits mTOR activity via the
phosphorylation of the tumor suppressor tuberous sclerosis
complex 2 (TSC2). As such, western blotting analysis revealed
the subsequent inhibition of the S6 protein phosphorylation
indicating that conventional targets of metformin are affected in
our cells. Based on these data, a combination with therapies
directed against PI3K/AKT/mTOR may be an option to
potentiate anticancer effects, as recently suggested [32]. Indeed,
combination of metformin with BEZ235, a dual mTOR and PI3K
inhibitor [33] gave synergistic results in all the three sarcoma
histotype (CI,0.9) (Table 2).
Besides inhibiting protein synthesis, AMPK may also alter the
process of cell division and cell death. Specifically, metformin was
found to decrease the expression of many genes involved in mitosis
[34] and may alter cell proliferation or induce cell death
depending on the status of p53 [35]. In our cells metformin
sensitivity did not vary in relation to p53 status. Most of our cell
lines display mutated p53 (Table 1) but no induction of apoptosis
was observed after metformin exposure (data not shown). In
contrast, in the Ewing sarcoma cells TC-71, SK-N-MC and 6647,
showing a truncation (TC-71) or major deletions (SK-N-MC)
inactivating p53 transcriptional activity, or carrying the single
point mutation S241F in the DNA binding domain which retains
part of the wt-p53 activity (6647), metformin treatment led to
accumulation of cells in G1 phase (Figure 3D). Effects on cell cycle
were similar in cells sensitive or resistant to anti-IGF1R drugs,
again sustaining that metformin effects were independent from
IGF1R or IR expression. The degree of G1 cell accumulation as
well as of cell proliferation inhibition, as shown by Ki-67 staining
(Figure 3D), reflects the different sensitivity of TC-71, SK-N-MC,
6647 cells to metformin, further confirming that in the most
sensitive sarcoma histotype metformin mainly displays a cytostatic
effect. As a consequence, to be therapeutic relevant metformin
should be associated with chemotherapy. Combined treatments
with vincristine, doxorubicin, actinomycin-D and ifosfamide, the
main drugs currently used in the therapy of sarcoma patients
[36,37], showed that metformin produced significant increases in
the efficacy of chemotherapeutic agents, with synergistic or
additive effects (Table 2). Despite previous evidences showed a
role of p53 status in the response to drug-drug combination
[38,39], we failed to observe a such a relationship in our cells.
Growth inhibitory effects of metformin were also confirmed in
chemoresistant sarcoma cell lines (Figure 1C). Metformin was
active either in Ewing sarcoma (TC/DOXO8) or osteosarcoma
(U-2/DOXO35) cells resistant to multiple drugs (e.g. doxorubicin,
epirubicin, vincristine) [26,27] confirming its therapeutic potential
in the management of sarcomas.
The synergistic in vitro effects with vincristine led us to verify the
efficacy of metformin also in vivo against TC-71 xenografts. Despite
the significant effects observed in vitro, we failed to observe any
reduction of tumor growth when metformin was used alone. Mice
bearing tumors 7 days after cell injection were treated with
metformin. Either injection near the tumors or oral administration
of metformin lacked to give tumor growth reduction (Figure 4A).
At the highest dose (500 mg/Kg) oral administration of metformin
was unable to inhibit tumor growth, or it even seems to increase it.
In addition, combination with vincristine lacked to give any
advantage with respect to vincristine alone (Figure 4A).
To understand these discrepancies between in vitro and in vivo
data, we analyzed the possible impact of hypoxia on metformin
efficacy in Ewing sarcoma cells. Hypoxia is an important condition
in the tumor cell microenvironment. Robust tumour growth
requires the presence of a local vascular network that supplies both
oxygen and nutrients to tumour cells. However, a highly
proliferating mass of tumour cells, such as Ewing sarcoma,
develops faster than the vasculature, and tumour cells rapidly meet
up with an avascular environment deficient in oxygen, i.e.
hypoxic. A large fraction of primary Ewing sarcoma accumulates
the hypoxia-inducible factor HIF-1a [40,41] a key transcription
factor that regulates genes that are exploited by tumour cells for
survival, resistance to treatment and escape from a nutrient-
deprived environment [42], presumably reflecting hypoxia induc-
tion in those tissues. In TC-71 xenografts, we could indeed
confirm the presence of several hypoxic regions, as shown by
nuclear accumulation of HIF-1a (Figure S1). We thus determined
whether the culture environment (normoxia or hypoxia) influ-
enced the effect of metformin on Ewing sarcoma viable cell
number. TC-71 and ASP14, a cellular variant of A673 EWS cell
line reported to have a functionally HIF-1alpha activated pathway
in response to hypoxia [43], were grown in normal or hypoxia
conditions and exposed to metformin alone or in association with
vincristine. Both cell lines were statistically significantly less
sensitive to metformin as well as to metformin plus vincristine in
hypoxia compared to normoxia (Figure 4B). Stabilization of HIF-
1a protein confirmed the hypoxic culture conditions in these
experiments (Figure 4C). Hypoxic conditions counteracted the
inhibitory effects of metformin possibly by preventing the
metformin–induced phosphorylation of AMPK (Figure 4C). This
appeared to be confirmed in vivo. We could observe a great
heterogeneity with respect to phosphorylation of AMPK inside
xenografts treated with 500 mg/kg/die of metformin. Quite
interestingly, the activation of the kinase was observed only in
the areas that were found to be negative for HIF-1a expression. In
Metformin Activity in Sarcomas
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contrast, in the hypoxic regions, as indicated by HIF-1a positivity,
we did not observe the phosphorylation of AMPK (Figure 4D).
This observation is only explorative and need validation but
confirms our in vitro evidences, supporting the need of deeper
studies comparing activity of metformin in normoxia and hypoxia.
Discussion
Development of new complementary biomolecular approaches
helping to keep treatment-related toxicity to a minimum and to
optimize systemic-disease control is still an urgent need for patients
with sarcomas. Scientists have tried to fill this therapy vacuum by
working on identification of new therapeutic targets, including
components of the IGF system [44]. However, development of
drugs is difficult for rare tumors and lack of novel drugs strongly
has limited any substantial improvements in the field. Metformin
may represent a possibility that deserves to be explored,
particularly in pediatric sarcomas. The drug is inexpensive,
relatively safe and can be potentially used in rational combinations
with other drugs, as an adjuvant therapy to potentiate conven-
tional and targeted agents [10,19,45]. There are no doubts that
IGF system is important for the pathogenesis and progression of
sarcomas [46]: cells produce ligands and express the receptors
creating a complex network of autocrine stimulations that may
sustain tumor growth based either on IGF1/IGF1R or IGF2/IR
axis [5,9]. In this paper, we demonstrated that metformin was
equally effective in sarcoma cells sensitive or resistant to different
drugs, including conventional or anti-IGF1R agents. In addition,
metformin was still able to inhibit sarcoma cell growth in the
presence of IGFs, a fact particularly relevant for bone tumors that
are exposed to high concentrations of these factors either through
autocrine tumor production or IGFs release from bone matrix
during tumor growth and bone disruption. Thus, metformin
appears as a very attractive adjuvant drug in vitro. Among the
three most common solid tumors in pediatric age, Ewing sarcoma
was confirmed to be the most sensitive one, in keeping with its
higher sensitivity to agents affecting IGF system [47,48]. However,
also among Ewing sarcoma cell lines, the level of sensitivity to the
drug varied remarkably. Understanding the link between genetic
variations and response to drugs would be essential to move
towards personalized treatment. Metformin requires the organic
cation transporters such OCT1/2 to be transported into cell,
whereas its extrusion is facilitated by the multidrug and toxin
extrusion 1 protein (MATE1). Polymorphisms or mutations in the
genes encoding for these transporters have been described and
may affect metformin effects as well as tumor LKB1 expression
[49]. In our cells, we observed that metformin inhibited tumor cell
proliferation independently of the levels of LKB1 but rather
through an increase of AMP/ATP ratio which leads to direct dose-
dependent activation of AMPK and subsequent inhibition of
mTORC1, inactivation of S6 kinase and general reduction of
protein synthesis. Through these events, and in relation to the level
of inhibition in the different cells, metformin reduces cell growth
and induces cell-cycle arrest at G1 phase. Despite that most of
sarcoma cell lines display deficient p53 functions [50] metformin
fails to induce apoptosis, thus suggesting that the drug may have
clinical value in combination with other agents rather than alone.
Given its inhibitory effects on mTOR signaling pathway,
metformin may indeed serve as a chemosensitizer with respect
to different type of drugs. Several reports showed that metformin
may cooperate with different chemotherapeutic agents to increase
their anticancer activity and provided evidence for a convergence
of metformin and drugs at the level of AMPK [45]. Through
AMPK-mediated inhibition of IRS-1 phosphorylation, metformin
participates to the inhibition of the IGF/insulin pathway and
shows potential advantages with respect to other mTOR
inhibitors, such as rapamycin [51,52]. This effect may be
particularly relevant for pediatric sarcoma. S6K was found to be
a crucial modifier of anti-IGF-IR drugs activity [53,54] and the
anti-IGF1R MAb Cixutumumab combined with the mTOR
Inhibitor Temsirolimus showed evidence of durable antitumor
activity in heavily pretreated EWS family tumors [55]. Here we
showed synergistic preclinical effects through combination of the
dual inhibitor mTOR/PI3K BEZ235 and metformin, confirming
Table 1. Lack of correlation between IGF-1R and IR expression and sensitivity to metformin in pediatric sarcomas.
HISTOTYPE
IGF-1R a
(ng/100 ug
of proteins)
IR b
(ng/100 ug
of proteins) Ratio IGF-1R:IR
IC50 of
metformin (mM) p53 Status
Ewing Sarcoma TC-71 2 0.32 6.25 8.160.4 p.Arg213X
SK-N-MC 3.69 2.87 1.28 17.465.9 c.170_572del
6647 0.81 4.13 0.2 19.966.4 p.Ser241Phe
RD-ES 3.74 2.39 1.56 39.967.6 p.Arg273Cys
SKES-1 1.82 6.03 0.30 14.562.2 p.Cys176Phe
LAP-35 2.38 0.56 4.25 18.861.3 wt
Osteosarcoma U-2 OS 4.97 0.18 27.61 25.262.3 wt
Saos-2 2.38 1.33 1.79 . 50 del2 . EX4-EX8
IOR/OS-10 1.64 5.42 0.30 17.161.2 splicing ex9/10
MG63 2.33 0.27 8.6 23.862.1 wt
Rhabdomyosarcoma CCA 1.56 0.72 2.16 23.860.5 nd
RD/18 1.45 1.63 0.90 5.962.6 248 Arg-Trp
RH-30 3.20 3.53 0.89 16.360.7 273 Arg-Cys
aSpearman’s test r = 0.448, P.0.050.
bSpearman’s test r = –0,402, P.0.050.
cSpearman’s test r = 0.457, P.0.050.
doi:10.1371/journal.pone.0083832.t001
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Figure 1. In vitro sensitivity of Metformin in sarcomas. A) Cell growth was assessed by MTT assay after 72h exposure to Metformin (mM) in
seven Ewing sarcoma, four Osteosarcoma, and three Rhabdomyosarcoma cell lines and displayed as a percentage of survival over controls. Points,
mean of two independent experiments; bars, SE. B) Effects of metformin on sarcoma cells in anchorage independent conditions. Number of colonies
was determined after 7–10 days of growth in IMDM 10% FBS. Columns, mean of three independent experiments; bars, SE. Bars: mean of three
experiments 6 SE. *P , 0.05, ** P,0.01, ***P , 0.005 statistically significant differences by Student’s t test. Representative pictures of the effects of
the inhibitor on colonies formation in soft agar. Magnification x40; C) IC50 values of metformin in Ewing sarcoma (TC/Doxo8) and osteosarcoma (U-
2OS/Doxo35) chemoresistant cell lines.
doi:10.1371/journal.pone.0083832.g001
Figure 2. Metformin effects are independent to IGF system activation. A) Cell growth was assessed by MTT assay after 72h exposure to
Metformin (mM) in cells resistant to anti-IGF-1R agents (TC/AVE, TC/AEW, TC/CP) where recently we demonstrated an increased expression of IR-A
with a concomitant downregulation of IGF-1R and displayed as a percentage of survival over controls. Points, mean of two independent experiments;
bars, SE; B) After overnight starvation, TC-71 and 6647 EWS cells were exposed to indicate concentration of metformin and/or IGF-1 and/or Insulin in
IMDM containing 1% FBS for 48h. Cell growth was assessed by trypan blue assay and shown as percentage of growth over untreated controls. C)
Starved cells were exposed to metformin (10 mM) for 4h in IMDM plus 1% FBS than stimulated with IGF-1 (50 ng/ml) or Insulin (10 nM) for 15min.
After harvesting, cells were lysed and prepared for immunoblot analyses for p-ERK and total ERK. b-Actin was used as loading control.
doi:10.1371/journal.pone.0083832.g002
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Table 2. In vitro combination study of metformin with conventional and targeted drugs in sarcoma cells.
Drug combination Ewing sarcoma(CI ± SE) Osteosarcoma(CI ± SE) Rhabdomyosarcoma(CI ±SE)
TC-71 SK-N-MC 6647 U-2OS RD/18
Metformin + Doxorubicin 0.08760.005 0.34460.02 0.67060.007 0.89760.06 0.99760.09
Metformin + IFO 0.75160.05 0.93560.154 0.90260.04 0.72360.06 0.66660.15
Metformin + NVP-BEZ235 0.58960.21 0.36560.08 0.22760.02 0.56460.11 0.45960.122
Metformin + Vincristin 0.50760.03 0.73660.02 0.46260.02 ND ND
Metformin + Actinomycin-D 0.76060.03 0.79660.124 1.73860.24 ND ND
doi:10.1371/journal.pone.0083832.t002
Figure 3. Analysis of metformin targets in Ewing sarcoma cell lines. A) protein expression levels of LKB1 in a panel of Ewing and
osteosarcoma cell lines. b-Actin was used as loading control. B) Left Graph showing cellular ATP levels (RLUs) as a percentage of control in control and
metformin treated ES cells. Right ES cells were treated as described in material and methods, and cellular lactate levels were measured using a
colorimetric assay kit (Abcam). Graph shows L-lactate concentration. Values are expressed as mean6 SEM and significance (*) p,0.05; (**) p,0.01 as
indicated. C) Metformin activity on AMPK and mTOR signaling on Ewing sarcoma cell lines. Western Blotting analysis of metformin-treated cells TC-
71, SK-N-MC and 6647. Cells were treated with metformin (10 mM) for the indicated time points (30min-24h). Immunoblot analysis was carried out
using antibodies against phosphorylated AMPKa (Thr172), AMPKa, phosphorylated pS6K (Ser240/244), pS6, and b-actin as normalization. D) Analysis of
Metformin (10 mM) effects on cell cycle over 48h treatment in three Ewing sarcoma cell lines (TC-71, SK-N-MC, 6647), together with two anti-IGF1R
agents resistant cells (TC/AVE, TC/AEW). Left panel, mean percentage of cells in different cell cycle phases as determined by flow cytometry analysis;
Righ panel, Ki-67 positive cells (Ki-67 labeling index). Data are shown as percentages of mean of three independent experiments and significance (*)
p,0.05 as indicated.
doi:10.1371/journal.pone.0083832.g003
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Figure 4. Hypoxia influence the effect of metformin on Ewing sarcoma. A) In vivo treatment with metformin in association or not with
vincristine (VCR) against TC-71 xenografts in athymic nude mice. Treatments began when tumors started being measurable at day +7 after
subcutaneous (s.c.) cell injection. Left graph, in vivo growth curves of TC-71 tumor volume (cm3) after s.c. injection of 56106 TC-71 cells in groups of 5
mice (treated groups) or 8 mice (Vehicle group). Vehicle, mice treated with PBS intratumor or water alone; metformin in drinking water, mice
receiving metformin 200 mg/Kg in drinking water; metformin intratumor, mice receiving intratumor injection of metformin 200 mg/Kg daily, 5 days
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with a cost-effective drug that this molecular targeting association
may be effective against patients that were previously found to be
resistant to targeted therapies through upregulation of mTOR
and/or ERK pathways [56]. In addition, accordingly with data
obtained in other tumors [18] metformin was found to potentiate
the in vitro antimitogenic activity of doxorubicin and vincristine
against sarcoma cells. The antiproliferative effect of metformin was
even found in doxorubicin-resistant variants of osteosarcoma and
Ewing sarcoma cells. This effect together with recent evidence that
metformin may protect against doxorubicin-induced cardiotoxicity
[57] and that it inhibits P-glycoprotein expression [58], one of the
major adverse biomarkers in osteosarcoma [59] further supported
its potential use as adjuvant drug. However despite these
encouraging results there are still some concerns regarding the
use of metformin. One of the main limitations in interpreting the
many in vitro studies is related to its concentration[12]. It is
certainly true that in vitro metformin is generally used at doses well
above the feasible therapeutic plasma levels in humans [60].
However, it is necessary to consider that in vitro cells are
conventionally maintained in non-physiological conditions, being
exposed to excessive concentrations of insulin, glucose and growth
factors which may account for the required elevated doses of
metformin. In addition, cells in vitro exposed to metformin do not
benefit from the indirect systemic effects of the drug on peripheral
tissues, which result in decreased circulating levels of insulin and
IGFs [10]. Further studies on more physiological models will be
required before establishing whether and how metformin may be
used in clinical settings. In vivo studies may be of help being able
to give a more comprehensive view of the mechanisms of action of
metformin. However, in contrast with what reported in xenografts
generated with prostate and lung cancer cell lines [19], neither
metformin injection near the tumor nor oral administration were
able to decrease Ewing sarcoma tumor growth. Oral administra-
tion of metformin was found to be ineffective also in combination
with vincristine despite the synergistic effects observed in vitro.
Reasoning on so different metformin effects in vitro and in vivo we
decided to explore the possible involvement of hypoxia, a major
feature of solid tumors. Decreased availability of oxygen was
indeed reported to increase patient treatment resistance and favor
tumor progression [61]. Mainly through activation of HIF1-alpha,
hypoxia promotes angiogenesis and initiates a cascade of events
that allows tumor cells to continue to proliferate. It was recently
shown that Ewing sarcoma cells adapt to hypoxia by redefining
their transcriptome and acquiring a distinct hypoxic phenotype
characterized by increased invasiveness and anchorage-indepen-
dent growth [41]. EWS-FLI1, the genetic hallmark of Ewing
sarcoma [62], and HIF-1a were found to collaborate in both
synergistic and antagonistic ways to regulate cellular metabolism
under hypoxia. Interestingly, the majority of EWS-FLI1 regulated
genes showed opposite transcriptional effects in normoxia or
hypoxia conditions, such as the survival factor, IGFBP-3, which
has previously been shown to be suppressed by EWS-FLI1 in
normoxia but highly upregulated under hypoxia or by the pro-
apoptotic gene BAX, strongly downregulated in hypoxia [41]. As
recently reported, these changes may contribute to HIF-1a
dependent protection of Ewing cells from anti-cancer drug- or
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-
induced apoptosis [43,63]. In addition, hypoxia has a major effect
on cell metabolism. Through the increase in HIF-mediated
expression of both glucose transporters and enzymes of the
glycolytic pathway, hypoxia contributes to favor cytoplasmic
conversion of pyruvate to lactic acid and glycolysis. In Ewing
sarcoma, the tumor-associated chimeric gene EWS-FLI1 is known
to induce the accumulation of hypoxia-induced transcription
factor HIF-1a [41] and cells have been recently shown to
simultaneously activate mitochondrial respiration and high levels
of glycolysis [64]. It is thus possible that while in normoxia the
metformin- induced glycolytic shift is able to generate a stress
sufficient for cells to induce direct activation of AMPK, in hypoxia
the accumulation of HIF1 may make respiration more efficient
[65] and protect cells from damages, including energy perturba-
tions induced by metformin. Besides confirming previous evidence
which showed how hypoxia may be amajor factor in the tumor
microenvironment of Ewing sarcoma [41,43,63], our findings
suggest a note of caution in the general enthusiasm that is linked to
clinical use metformin and other biguanides. Although the effects
of metformin in tumor prevention seem to be really encouraging,
its efficacy in tumor therapy is still under evaluation. Mechanisms
of action are still incompletely defined and require deeper cellular-
context definition. In this paper we suggest that the impact of
hypoxia should be also considered to obtain full exploitation of the
remarkable advantages of this clinically attracting drug.
Supporting Information
Figure S1 Immunohistochemical evaluation of HIF-
1alpha in xenografts. Representative figures are shown
(magnification X100). Enlargement of a detailed section is shown
to highlight nuclei staining (magnification X200 and X400).
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weekly. Right graph, in vivo growth curves of TC-71 tumor volume after s.c. injection of 7.56106 TC-71 cells in groups of 5 mice. Vehicle, mice treated
with PBS; Metformin, mice treated daily, 5 days weekly with 500 mg/kg Metformin p.o. (gavage); VCR, mice treated with 1 mg/kg/d i.p. for 2
consecutive days; Metformin+VCR, combined therapy with Metformin 500 mg/Kg p.o. and VCR 1 mg/Kg/d i.p. B) Decrease responsiveness to
metformin in hypoxia respect to normoxia environment. In hypoxia experiments, TC-71 and ASP-14 Ewing sarcoma cells were pre-treated for 18h
with hypoxia mimetic agent CoCl2 (200 uM) than exposed for 48h to different concentration of metformin (10–30 mM) or left untreated. In
combination experiments, TC-71 Ewing sarcoma cells were pre-treated for 18h with CoCl2 (200 uM) than exposed for 48h to metformin (10 mM)
alone or in combination with different concentrations of vincristine (0.3–10 ng/ml). Effects of metformin on cell growth were assessed by trypan bleu
assay and shown as percentage of survival over untreated control. *P , 0.05, ** P,0.01 statistically significant differences by Student’s t test. C)
Western blotting analysis of AMPKa phosphorylation levels under hypoxia and normoxia conditions after metformin (10–30 mM) treatment. TC-71
and ASP-14 EWS cells were pre-treated for 18h with CoCl2 (200 uM) than exposed for 4h to different concentration of metformin (10–30 mM) or left
untreated. Accumulation of HIF-1a protein confirmed the induction of hypoxia; b-actin was used as loading control. D) Immunohistochemical
evaluation of HIF-1a and phospho-AMPKa in hypoxic (left panel) and normoxic areas (righ panel) in xenografts. Representative figures are shown
(magnification X100).
doi:10.1371/journal.pone.0083832.g004
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